People · Operator

Bob John Lash, M.D.

Named in public records as an officer, director or promoter · active 2009–2009 · Other Health Care

1
Companies
3
Filings
$8.2M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Vioptix IncOther Health CareSeed$8.2M$70.1M2009
Operator network

Bob John Lash, M.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

W. Gregory Shearer · 2 companies · 1 sharedW. Gregory ShearerAlex A. Keller, M.D. · 1 companies · 1 sharedAlex A. Keller, M…Alex John Keller, M.D. · 1 companies · 1 sharedAlex John Keller,…George A. Gardiner · 1 companies · 1 sharedGeorge A. GardinerJennifer John Hamilton · 1 companies · 1 sharedJennifer John Ham…Jian-min A. Mao, Ph.D. · 1 companies · 1 sharedJian-min A. Mao, …Jian-min John Mao, Ph.D. · 1 companies · 1 sharedJian-min John Mao…L. John Lloyd · 1 companies · 1 sharedL. John LloydMark A. Lonsinger · 1 companies · 1 sharedMark A. LonsingerMark John Lonsinger · 1 companies · 1 sharedMark John Lonsing…Michael A. Cross · 1 companies · 1 sharedMichael A. CrossScott E. Coleridge · 1 companies · 1 sharedScott E. ColeridgeVictor A. Colunga · 1 companies · 1 sharedVictor A. ColungaVioptix Inc · $8.2M raisedVioptix IncBob John Lash, M.D.BM
Bob John Lash, M.D. Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Bob John Lash, M.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
W. Gregory Shearer12
L. John Lloyd11
Jennifer John Hamilton11
Scott E. Coleridge11
Alex John Keller, M.D.11
Mark John Lonsinger11
Jian-min A. Mao, Ph.D.11
George A. Gardiner11
Alex A. Keller, M.D.11
Michael A. Cross11
Mark A. Lonsinger11
Jian-min John Mao, Ph.D.11
Victor A. Colunga11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.